Abstract: FR-PO171
Effect of Hypomagnesemia on Vascular Calcification in Peritoneal Dialysis Patients
Session Information
- Bone and Mineral Metabolism: Phosphorus, FGF23, Vascular Calcification
November 08, 2019 | Location: Exhibit Hall, Walter E. Washington Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Bone and Mineral Metabolism
- 402 Bone and Mineral Metabolism: Clinical
Authors
- Kang, Minjung, Seoul National University Hospital, Seoul, Korea (the Republic of)
- Kang, Eunjeong, Seoul National University Hospital, Seoul, Korea (the Republic of)
- Ryu, Hyunjin, Seoul National University Hospital, Seoul, Korea (the Republic of)
- Ahn, Curie, Seoul National University Hospital, Seoul, Korea (the Republic of)
- Oh, Kook-Hwan, Seoul National University Hospital, Seoul, Korea (the Republic of)
Background
Vascular calcification is a non-traditional risk factor for cardiovascular disease in patients with chronic kidney disease (CKD) and main cause of this is disturbance in the mineral and bone metabolism. Magnesium (Mg) was known as a calcification inhibitor and there was a high prevalence of hypomagnesemia in peritoneal dialysis (PD) patients. However, a longitudinal study of the effects of hypomagnesemia on vascular calcification in PD patients was rare.
Methods
167 patients with PD were included from Seoul National University Hospital. We investigated the relationship between lower serum magnesium and vascular calcification progression. Patients were categorized as hypomagnesemia (n=20), normomagnesemia (n=85), and hypermagnesemia (n=62). Vascular calcification was assessed by abdominal aortic calcification (AAC) score with lateral lumbosacral X-ray. The study end point was vascular calcification progression, defined as the change in AAC score per year >0.
Results
During the median follow-up period of 3.1 years [interquartile range 2.0-4.3 years; maximum 7.6 years], 38 (42.7%) patients developed vascular calcification progression. In a multivariable logistic regression model, the hypomagnesemia group was associated with higher risk of vascular calcification progression (C1, serum Mg ≤ 1.7 mg/dl, OR 27.3 [1.07 – 691.2]; P=0.045), as compared with the normal range magnesium group. All-cause mortality was not associated with hypomagnesemia in a multivariable hazard model (C1, serum Mg ≤ 1.7 mg/dl, HR 0.7 [0.07 – 6.89]; P=0.755).
Conclusion
Hypomagnesemia is associated with vascular calcification progression in peritoneal dialysis patients.